Evidence map›Paper›PMID 38363314›Full record

Trial reportChild's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery2024

Predictors of neurocognition outcomes in children and young people with primary brain tumor presenting to tertiary care hospitals of Karachi, Pakistan: a prospective cohort study.

Nida Zahid, S Ather Enam, Thomas Mårtensson, Iqbal Azam, Naureen Mushtaq, Mariya Moochhala, Farrukh Javed, Faiza Kausar, Aneesa Hasan, Lal Rehman and 4 more

Registry-linked trialOpen access · hybridAbstract readClinical TrialMulticenter Study
In one paragraph

Trial report in Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05709522 (Neurocognitive and Psychosocial Outcomes Among Pediatric Brain Tumor and Blood Cancer Patients Presenting to a Tertiary Care Hospital of Karachi, Pakistan), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05709522 unknown statusnot on this map

Neurocognitive and Psychosocial Outcomes Among Pediatric Brain Tumor and Blood Cancer Patients Presenting to a Tertiary Care Hospital of Karachi, Pakistan: A Prospective Cohort Study

TypeobservationalSponsorAga Khan UniversityRan2020 to 2023Enrolled80ConditionsBrain Tumor, Pediatric, Blood CancerArmsNeurocognitive tools
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 3 countries.

Nida ZahidDepartment of Surgery, Aga Khan University, Karachi, Pakistan. nida.zahid@aku.edu.ORCID 0000-0001-8812-9463
S Ather EnamDepartment of Surgery, Aga Khan University, Karachi, Pakistan.
Thomas MårtenssonGlobal Health and Migration Unit, Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.
Iqbal AzamDepartment of Community Health Sciences, Aga Khan University, Karachi, Pakistan.
Naureen MushtaqDepartment of Pediatric Oncology, Aga Khan University, Karachi, Pakistan.
Mariya MoochhalaDepartment of Psychiatry, Aga Khan University, Karachi, Pakistan.
Farrukh JavedDepartment of Neurosurgery, Jinnah Postgraduate Medical Centre, Karachi, Pakistan.
Faiza KausarDepartment of Surgery, Aga Khan University, Karachi, Pakistan.
Aneesa HasanDepartment of Surgery, Aga Khan University, Karachi, Pakistan.
Lal RehmanDepartment of Neurosurgery, Jinnah Postgraduate Medical Centre, Karachi, Pakistan.
M Nouman MughalDepartment of Surgery, Aga Khan University, Karachi, Pakistan.
Sadaf AltafDepartment of Pediatric Oncology, Aga Khan University, Karachi, Pakistan.
Salman KirmaniDivision of Women & Child Health, Aga Khan University, Karachi, Pakistan.
Nick BrownGlobal Health and Migration Unit, Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden. nick.brown@kbh.uu.se.ORCID 0000-0003-1789-0436
Aga Khan University · PKJinnah Postgraduate Medical Center · PKUppsala University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPrimary brain tumors are a common cause of morbidity and mortality in children and young people (CYP) globally. Impaired neurocognitive function is a potential severe consequence in primary brain tumor (PBT) survivors. There are no in-depth studies from low- and middle-income countries (LMICs) to inform management and follow-up. The research questions of this study were as follows: Are the sociodemographic factors (lower age of CYP, female gender, low socioeconomic status, low parental education), disease-related factors (high grade of tumor, presence of seizures, presence of hydrocephalous), and treatment-related factors (adjuvant therapy, no surgical intervention, post-treatment seizures, placement of shunts) associated with decline in neurcognition outcomes 12 months post-treatment in CYP with PBTs?

methodsA prospective cohort study was conducted from November 2020 to July 2023 at the Aga Khan University Hospital and Jinnah Postgraduate Medical Centre, tertiary care hospitals in Karachi, Pakistan. All CYP aged 5 to 21 years with a newly diagnosed PBTs were eligible. The neurocognition assessment was undertaken by a psychologist at two points, i.e., pre-treatment and at 12 months post-treatment using validated tools. The verbal intelligence was assessed by Slosson Intelligence tool, revised 3rd edition (SIT-R3), perceptual reasoning by Raven's Progressive Matrices (RPM), and the Processing Speed Index by Wechsler Intelligence Scale (WISC V) and Wechsler Adult Intelligence Scale (WAIS-IV). The data were analyzed by STATA version 12 software. Generalized estimating equation (GEE) was used to determine the factors associated with the mean change in 12 months post-treatment verbal and non-verbal neurocognition scores. Unadjusted and adjusted beta coefficients with their 95% confidence intervals were reported.

resultsA total of 48 CYPs with PBTs were enrolled, 23 (48%) of them were lost to follow-up and 10 (21%) died. The remaining 25 (52%) were reassessed 12 months after treatment. On multivariable analysis, a significant decline in verbal intelligence scores at 12 months was predicted by post-treatment seizures beta =  - 20.8 (95% CI, - 38.2, - 3.4), mothers having no formal educational status and lower household monthly income. Similarly, a significant decline in perceptual reasoning scores was also predicted by post-treatment seizures beta =  - 10.7 (95% CI, - 20.6, - 0.8), mothers having no formal education and having lower household monthly income. Worsening of processing speed scores at 12 months post-treatment were predicted by tumor histology, post-treatment seizures beta =  - 33.9 (95% CI, - 47.7, - 20.0), lower educational status of the mother, and having lower household monthly. However, an improvement was seen in processing speed scores after surgical tumor resection.

conclusionIn this novel study, the post-treatment mean change in verbal and non-verbal neurocognition scores was associated with sociodemographic, tumor, and treatment factors. These findings may have potential implications for targeted early psychological screening of higher risk CYP with PBTs. Identification of these predictors may serve as a foundation for developing more cost-effective treatment thereby alleviating the burden of neurocognitive morbidity. However to establish generalizability, future research should prioritize larger-scale, multicountry studies. (Trial registration: ClinicalTrials.gov Identifier: NCT05709522).

Indexed as

Brain NeoplasmsTertiary Care CentersAdolescentChildChild, PreschoolCohort StudiesFemaleHumansMaleNeuropsychological TestsPakistanProspective StudiesYoung AdultChildren and young peopleCohort studyNeurocognition outcomesPakistanPrimary brain tumor

Identifiers

PMID38363314
PMCPMC11111568
OpenAlexW4391883477

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.